TRANSACTION AGREEMENTTransaction Agreement • March 15th, 2017 • Arena Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Transaction Agreement (this “Agreement”) is entered into as of December 28, 2016 (the “Effective Date”) by and among 356 Royalty Inc., a company organized under the laws of Delaware having a principal place of business at 6154 Nancy Ridge Drive, San Diego, CA 92121 (“Arena”), Eisai Inc., a company organized under the laws of Delaware having a principal place of business at 100 Tice Blvd., Woodcliff Lake, New Jersey 07677 (“ESI”), and Eisai Co., Ltd., a company organized under the laws of Japan having a principal place of business at 4-6-10 Koishikawa Bunkyo-ku, Tokyo, Japan, 112-88 (“ECL”). “Eisai” shall mean (a) ESI, with respect to all rights and obligations of Eisai under this Agreement with respect to the ESI Territory (as defined below) and (b) ECL, with respect to all rights and obligations of Eisai under this Agreement with respect to the ECL Territory (as defined below). Each of Arena and Eisai may be referred to in this Agreement individually as a “Party” and collectively
SUPPLY AGREEMENTSupply Agreement • March 15th, 2017 • Arena Pharmaceuticals Inc • Pharmaceutical preparations • New York
The above are general guidelines and individual awards may vary. To be eligible for an award, the employee must agree to the terms of a written bonus plan or agreement to be provided by Arena. The bonus is intended for selected individuals who stay in good-standing with Arena through at least until the earlier of: (1) […***…] following the Effective Date, or (2) delivery of at least […***…] lorcaserin tablets as ordered by Eisai. […***…]. The aggregate amount of bonuses offered to selected employees will not exceed CHF […***…] without the agreement of the Parties.
